These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 7803944)

  • 1. Pharmacological advances in the treatment of glaucoma.
    Serle JB
    Drugs Aging; 1994 Sep; 5(3):156-70. PubMed ID: 7803944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
    Gebhardt DO
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):275. PubMed ID: 10086159
    [No Abstract]   [Full Text] [Related]  

  • 3. [Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
    Hoyng PF; Rasker MT
    Ned Tijdschr Geneeskd; 1998 Sep; 142(39):2138-41. PubMed ID: 9856229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive intraocular pressure lowering effect of various medications with latanoprost.
    O'Connor DJ; Martone JF; Mead A
    Am J Ophthalmol; 2002 Jun; 133(6):836-7. PubMed ID: 12036683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments in the drug treatment of glaucoma.
    Hurvitz LM; Kaufman PL; Robin AL; Weinreb RN; Crawford K; Shaw B
    Drugs; 1991 Apr; 41(4):514-32. PubMed ID: 1711957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New medical therapies for glaucoma.
    Drake MV
    Int Ophthalmol Clin; 1996; 36(2):53-60. PubMed ID: 8950633
    [No Abstract]   [Full Text] [Related]  

  • 8. Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.
    Razeghinejad MR; Sawchyn AK; Katz LJ
    Expert Opin Pharmacother; 2010 Apr; 11(6):959-68. PubMed ID: 20307220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New topical medications in the treatment of glaucoma.
    Gandham SB
    J Ophthalmic Nurs Technol; 1997; 16(6):290-1. PubMed ID: 9460417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New drugs in glaucoma therapy].
    Gramer E
    Klin Monbl Augenheilkd; 1998 Jul; 213(1):aA10-2. PubMed ID: 9743931
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of brimonidine in the treatment of open-angle glaucoma.
    Wilensky JT
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S3-7. PubMed ID: 8970244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care.
    Bateman DN; Clark R; Azuara-Blanco A; Bain M; Forrest J
    Br J Ophthalmol; 2002 May; 86(5):551-4. PubMed ID: 11973253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical carbonic anhydrase inhibitors.
    Talluto DM; Wyse TB; Krupin T
    Curr Opin Ophthalmol; 1997 Apr; 8(2):2-6. PubMed ID: 10168353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on topical carbonic anhydrase inhibitors.
    Herkel U; Pfeiffer N
    Curr Opin Ophthalmol; 2001 Apr; 12(2):88-93. PubMed ID: 11224713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
    García Sanchez J
    Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of glaucoma medication in the pediatric population.
    Coppens G; Stalmans I; Zeyen T; Casteels I
    J Pediatr Ophthalmol Strabismus; 2009; 46(1):12-8. PubMed ID: 19213271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of latanoprost 0.005% once daily and its effect on intraocular pressure as primary or adjunctive therapy.
    Smith SL; Sine CS; Pruitt CA; Stewart WC
    J Ocul Pharmacol Ther; 1999 Feb; 15(1):29-39. PubMed ID: 10048345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New developments in drug therapy of glaucoma].
    Pfeiffer N
    Ophthalmologe; 1992 Feb; 89(1):W1-13. PubMed ID: 1349844
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in topical glaucoma therapy.
    Willis AM; Diehl KA; Robbin TE
    Vet Ophthalmol; 2002 Mar; 5(1):9-17. PubMed ID: 11940242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.